Gilead Sciences (NASDAQ:GILD) Shares Acquired Rep. Marjorie Taylor Greene

Representative Marjorie Taylor Greene (R-Georgia) recently bought shares of Gilead Sciences, Inc. (NASDAQ:GILD). In a filing disclosed on May 06th, the Representative disclosed that they had bought between $1,001 and $15,000 in Gilead Sciences stock on May 5th.

Representative Marjorie Taylor Greene also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of AbbVie (NYSE:ABBV) on 5/5/2025.
• Purchased $1,001 – $15,000 in shares of Occidental Petroleum (NYSE:OXY) on 5/5/2025.
• Purchased $1,001 – $15,000 in shares of Paychex (NASDAQ:PAYX) on 5/5/2025.
• Purchased $1,001 – $15,000 in shares of MercadoLibre (NASDAQ:MELI) on 5/5/2025.
• Purchased $1,001 – $15,000 in shares of Starbucks (NASDAQ:SBUX) on 5/5/2025.
• Purchased $1,001 – $15,000 in shares of BP (NYSE:BP) on 5/5/2025.
• Purchased $1,001 – $15,000 in shares of BHP Group (NYSE:BHP) on 5/5/2025.
• Purchased $1,001 – $15,000 in shares of Advanced Micro Devices (NASDAQ:AMD) on 5/5/2025.
• Purchased $1,001 – $15,000 in shares of Alphabet (NASDAQ:GOOG) on 5/5/2025.
• Purchased $1,001 – $15,000 in shares of Impinj (NASDAQ:PI) on 5/5/2025.

Gilead Sciences Price Performance

Shares of GILD stock opened at $98.90 on Thursday. The company has a market capitalization of $123.15 billion, a P/E ratio of 267.30, a P/E/G ratio of 0.71 and a beta of 0.26. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $119.96. The stock has a 50 day moving average of $107.95 and a two-hundred day moving average of $99.09.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, beating analysts’ consensus estimates of $1.77 by $0.04. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The company had revenue of $6.67 billion for the quarter, compared to the consensus estimate of $6.77 billion. During the same period in the previous year, the business earned ($1.32) earnings per share. The company’s quarterly revenue was down .3% on a year-over-year basis. As a group, equities analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 27th. Investors of record on Friday, June 13th will be given a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a yield of 3.20%. The ex-dividend date is Friday, June 13th. Gilead Sciences’s dividend payout ratio (DPR) is presently 66.53%.

Insiders Place Their Bets

In related news, CFO Andrew D. Dickinson sold 137,676 shares of the stock in a transaction dated Wednesday, February 12th. The stock was sold at an average price of $102.22, for a total transaction of $14,073,240.72. Following the completion of the sale, the chief financial officer now owns 171,223 shares in the company, valued at approximately $17,502,415.06. This trade represents a 44.57 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Over the last three months, insiders have sold 160,605 shares of company stock valued at $16,718,136. Insiders own 0.27% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the company. JPMorgan Chase & Co. lifted their price objective on Gilead Sciences from $120.00 to $130.00 and gave the company an “overweight” rating in a research report on Thursday, March 27th. Oppenheimer lowered their price target on shares of Gilead Sciences from $132.00 to $125.00 and set an “outperform” rating for the company in a research report on Friday, April 25th. BMO Capital Markets raised their price target on Gilead Sciences from $110.00 to $115.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 12th. DZ Bank raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 price target for the company in a research note on Thursday, February 13th. Finally, Piper Sandler boosted their price target on shares of Gilead Sciences from $105.00 to $110.00 and gave the company an “overweight” rating in a report on Wednesday, February 12th. Nine analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Gilead Sciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $110.55.

Institutional Trading of Gilead Sciences

Hedge funds have recently made changes to their positions in the stock. Smallwood Wealth Investment Management LLC bought a new position in shares of Gilead Sciences in the first quarter worth approximately $25,000. Goodman Advisory Group LLC bought a new position in Gilead Sciences during the first quarter valued at approximately $29,000. HHM Wealth Advisors LLC grew its position in Gilead Sciences by 118.5% in the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 154 shares during the period. YANKCOM Partnership purchased a new stake in Gilead Sciences during the 4th quarter valued at $28,000. Finally, Core Alternative Capital boosted its stake in shares of Gilead Sciences by 370.8% in the 1st quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company’s stock worth $34,000 after buying an additional 241 shares during the last quarter. 83.67% of the stock is owned by institutional investors.

About Representative Greene

Marjorie Taylor Greene (Republican Party) is a member of the U.S. House, representing Georgia’s 14th Congressional District. She assumed office on January 3, 2021. Her current term ends on January 3, 2027.

Greene (Republican Party) is running for re-election to the U.S. House to represent Georgia’s 14th Congressional District. She declared candidacy for the 2026 election.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.